In the gastric cancer cell lines AGS and SNU-638, the PF treatment decreased cell viability and enhanced caspase-3 activity; however, with the knockdown of PERK, the PF treatment did not reduce cell viability or the increase of caspase-3 activity (Figure 5D,E). This evidence concerns the gene EIF2AK3 and gastric cancer.